| Literature DB >> 26283962 |
Sébastien Roger1, Ludovic Gillet2, Jean-Yves Le Guennec3, Pierre Besson4.
Abstract
Voltage-gated sodium channels (NaV) are molecular characteristics of excitable cells. Their activation, triggered by membrane depolarization, generates transient sodium currents that initiate action potentials in neurons and muscle cells. Sodium currents were discovered by Hodgkin and Huxley using the voltage clamp technique and reported in their landmark series of papers in 1952. It was only in the 1980's that sodium channel proteins from excitable membranes were molecularly characterized by Catterall and his collaborators. Non-excitable cells can also express NaV channels in physiological conditions as well as in pathological conditions. These NaV channels can sustain biological roles that are not related to the generation of action potentials. Interestingly, it is likely that the abnormal expression of NaV in pathological tissues can reflect the re-expression of a fetal phenotype. This is especially true in epithelial cancer cells for which these channels have been identified and sodium currents recorded, while it was not the case for cells from the cognate normal tissues. In cancers, the functional activity of NaV appeared to be involved in regulating the proliferative, migrative, and invasive properties of cells. This review is aimed at addressing the non-excitable roles of NaV channels with a specific emphasis in the regulation of cancer cell biology.Entities:
Keywords: cancer; cell excitability; invasion; sodium; voltage-gated sodium channel
Year: 2015 PMID: 26283962 PMCID: PMC4518325 DOI: 10.3389/fphar.2015.00152
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
List of the non-nervous tissue cancers in which Na.
| Prostate | Cancer | Biopsies | NaV1.8 | Yes (IH); staining for NaV1.8 correlated with Gleason score: very low in normal epithelium, low in moderately aggressive stages, strong in highly aggressive cancer with appearance of staining in nucleus | Suy et al., | ||||
| PC-3 | NaV1.2 | NaV1.1 | 8.6 nM | nNaV1.7 | Invasion Motility (galvanotaxis) Motility (wound healing) | Laniado et al., | |||
| 22Rv1 | NaV1.1 | Suy et al., | |||||||
| DU-145 | NaV1.1 | Suy et al., | |||||||
| LnCaP | NaV1.2 | NaV1.1 | No current | Laniado et al., | |||||
| Mat-Ly-Lu (rat) | NaV1.1 | 18 nM | nNaV1.7 | Invasion (galvanotaxis) Motility (wound healing) | Grimes et al., | ||||
| AT-2 (rat) | NaV1.1 | No current | — | — | Grimes et al., | ||||
| Non-Cancer | PNT2 (normal, immortalized) | ? | No current | — | — | Mycielska and Djamgoz, | |||
| Breast | Cancer | Biopsies | NaV1.5 | Yes (IH, RT-PCR) | Fraser et al., | ||||
| MDA-MB-231 | fNaV1.5 | ~2 μM | nNaV1.5 | Yes (RT-PCR) | Roger et al., | ||||
| promotion of proteolytic invadopodial activity Promotion of metastasis in immunodeficient mice | Driffort et al., | ||||||||
| MCF-7 | NaV1.5 | No current | — | — | Roger et al., | ||||
| MDA-MB-468 | ? | No current | Roger et al., | ||||||
| Lung | Small-cell lung cancer | H146 | ? | 215 nM | Current | ? | ? | Pancrazio et al., | |
| H128 | ? | ? | Current | ? | ? | Pancrazio et al., | |||
| H69 | NaV1.3 | TTX-S | Current | Endocytosis | ? | Pancrazio et al., | |||
| H209 | NaV1.3 | TTX-S | Endocytosis | ? | Onganer and Djamgoz, | ||||
| H510 | NaV1.3 | TTX-S | Endocytosis | ? | Onganer and Djamgoz, | ||||
| Non-small cell lung cancer | H460 | NaV1.3 | ~10 nM | NaV1.7 | Invasion | Roger et al., | |||
| Calu-1 | NaV1.1 | ~5 nM + ~1 μM | NaV1.1 | Invasion | Roger et al., | ||||
| H23 | NaV1.5 | ~10 nM | NaV1.6 | Invasion | Roger et al., | ||||
| A549 | NaV1.6 | No current | — | — | Roger et al., | ||||
| Non-cancer | NL20 (normal, immortalized) | NaV1.2 | No current | — | — | Roger et al., | |||
| BEAS-2B (normal, immortalized) | NaV1.1 | No current | — | — | Roger et al., | ||||
| Leukocytes | Leukemia | K562 | ? | ? | Current (type not identified) | ? | ? | Schlichter et al., | |
| K562 | No current | — | — | Yamashita et al., | |||||
| K562/ADM | ? | < 100 nM | Current (type not identified) | ? | ? | Yamashita et al., | |||
| CCRF-CEM | ? | < 150 nM | Current (type not identified) | ? | ? | Lee et al., | |||
| CEM/VLB100 | ? | < 150 nM | Current (type not identified) | ? | ? | Lee et al., | |||
| Jurkat (normal, immortalized) | NaV1.5 | ~900 nM | NaV1.5 | invasion | Fraser et al., | ||||
| Normal | Normal human lymphocytes | Current (type not identified) in three cells out of 90 | Cahalan et al., | ||||||
| Primary-cultured human monocytes-derived macrophages | NaV1.5 | NaV1.5 (IH)NaV1.6 (IH) | TTX-R | NaV1.5; protein localized in late endosomes | Phagocytosis, acidification of endosomes | Carrithers et al., | |||
| Pleura | Mesothelioma | Primary-cultured human malignant pleural mesothelioma cells | NaV1.2 | TTX-sensitive current | Increases | Fulgenzi et al., | |||
| Normal mesothelial cells | (Normal, immortalized) | No current | Fulgenzi et al., | ||||||
| Cervix | Cancer | Primary-cultured human cervical carcinoma cells | NaV1.1 | NaV1.6 (IH)NaV1.7 (IH) | TTX-sensitive current | NaV1.6-dependent invasion | Diaz et al., | ||
| Non-cancer | (Biopsies of normal uterine cervix) | NaV1.1 (very low) | NaV1.6 (IH)NaV1.7 (IH) | Diaz et al., | |||||
| Colon | Cancer | Biopsies | NaV1.5 (IH) | House et al., | |||||
| HT-29 | NaV1.5 (IH) | Current | NaV1.5-dependent invasion (shown with 30 μM TTX or siRNA) | House et al., | |||||
| SW620 | NaV1.5 (IH) | Current | NaV1.5-dependent invasion (shown with 30 μM TTX or siRNA) | House et al., | |||||
| SW480 | NaV1.5 (IH) | Current | NaV1.5-dependent invasion (shown with 30 μM TTX or siRNA) | House et al., | |||||
| Non-cancer | (Biopsies of normal colon) | NaV1.5 faint staining (IH) | House et al., | ||||||
| Ovary | Cancer | Anglne | NaV1.1 | NaV1.5 (IH) | — | Gao et al., | |||
| Caov-3 | NaV1.1 | NaV1.5 (IH) | TTX-R migration and invasion | Gao et al., | |||||
| SKOV-3 | NaV1.1 | NaV1.5 (IH) | TTX-R migration and invasion | Gao et al., | |||||
| Non-cancer | (Biopsies of normal ovary) | NaV1.1 | NaV1.5 (IH) | Yes (RT-PCR) | Gao et al., | ||||
| Primary-cultured luteinized cells of the granulosa | NaV (type not indicated) (RT-PCR) | NaVα protein (type non identified) detected with panNaVα antibody (WB, IH) | 6.8 nM | TTX-S current | Physiological luteolysis of normal corpus luteum cells of the ovary | Bulling et al., |
IH, immune-histochemical staining; nNa.
Figure 1Na. Normal epithelial cells are morphologically and functionally polarized (apico-basal polarization). They are tightly connected together by different cell junctions such as tight junctions, adherens junction, gap junctions, and desmosomes. They are associated to the basement membrane by hemidesmosomes composed of integrins. They are maintaining a particular organization of the cytoskeleton. Particularly, actin filaments (F-actin) form a cortical network under the plasma membrane that is determinant in keeping this polarized morphology. During the carcinogenetic process, cancer cells that survived to environmental constraints, and have been selected, have acquired multiple mutations conferring proliferative and immortality advantages. This process is responsible for the development of a primary in situ tumor that becomes invasive when some aggressive cancer cells gain the ability to degrade and migrate through the extracellular matrix (ECM). This second step is critical for invasive cancer cells to reach the blood circulation and eventually to colonize and form secondary tumors (metastases) in distant organs. Migrative cancer cells have lost their intercellular junctions, their apico-basal polarization and now display a front-rear polarization. The proteolysis of the ECM by cancer cells is dependent on the formation and activity of protrusive structures, enriched in F-actin, called invadopodia. All these changes in cell phenotype and behavior are obtained through the process called Epithelial-to-Mesenchymal Transition (EMT). NaVα proteins are abnormally expressed in highly invasive cancer cells, and are found in invadopodia (see magnification). They are co-localized with Na+-H+ exchangers type 1 (NHE-1) for which they enhance the protons extrusion activity. This leads to a peri–invadopodial acidification favorable to the activity of acidic cysteine cathepsins, released by cancer cells, and consequently to the ECM degradation. NaVα proteins are also proposed to increase the intracellular Ca2+ concentration through the participation of Na+-Ca2+ exchangers (NCX). NaVα activity, through a persistent window current, sustains Src kinase activity, the phosphorylation (Y421) of the actin nucleation-promoting factor cortactin, and the polymerization of actin filaments. Altogether, this suggests that NaVα activity in cancer cells enhances both the formation and the ECM degradative activity of invadopodia.
Figure 2Na. NaVα proteins allow the entry of Na+ into the cell. This entry of cations is known to depolarize the membrane potential (Vm) and to initiate action potentials in excitable cells. NaVα proteins also controls the intracellular concentration of Na+ that could be considered as a second messenger since it regulates, directly or indirectly, many signaling pathways involved in cell polarity, cell migration, and extracellular matrix (ECM) remodeling. These properties are involved in physiological cell migration and invasiveness, such as in organogenesis and tissue repairing and also in the pathological migration and invasiveness of cancer cells.